Prucalopride

Limits on what this shows

• Key null findings: The PubMed listing [16] and three web-search phrasings (mitochondria, mitophagy, mitochondrial biogenesis with prucalopride) returned no prucalopride mitochondrial-function study.
• At-risk subgroups: None identified.

Regulatory status

No mitochondrial statement in the label sections retrieved [1][2]. The label addresses cardiac risk only through QT (no relevant prolongation at 5 times the maximum dose) and MACE data [1].

Population evidence

Wang, Gu et al., Scientific Reports 2016 [7]: neonatal mouse cardiomyocytes and isolated mitochondria. Agonists were zacopride, BIMU and ML 10302; antagonist RS 23597-190. Prucalopride was not used. As summarized: zacopride lowered mitochondrial Ca2+ uptake (about 45% in normoxia, 52% in hypoxia); membrane potential did not change; respiratory control ratios were lower with 5-HT4 activation; BIMU prevented Ca2+-induced mitochondrial swelling much as cyclosporin A did. Prucalopride-named: caspase-9 activation fell in neurons under H2O2 [5], and prucalopride improved striatal dopamine in the MPTP mouse model [8]; neither measured mitochondrial function in the accessible text.

Mechanism

Hypothesized only: [7] reports 5-HT4 receptors on cardiac mitochondrial membranes. Whether prucalopride reaches or acts on them is not shown. Direction across the class data is mixed (lower respiratory control ratio but protection against permeability-transition swelling), so no burden direction is established.

Class cohort test

CLASS EXTRAPOLATION. Prucalopride was NOT in the cohort of [7]; the agonists studied were zacopride, BIMU and ML 10302. Real mitochondrial data exist for those members and the shared mechanism is 5-HT4 agonism, which supports yellow. Limits: neonatal mouse heart cells, not human, gut or neuron; prucalopride's access to mitochondria is unshown; selectivity and chemistry of the three ligands were not compared with prucalopride. Capped at yellow. No data from sibling dossiers were borrowed.

Counter-evidence held on record

Counter-evidence and confounding The cardiomyocyte work is receptor biology, not a drug-toxicity study, and the prucalopride-named neuronal work points toward protection. The cisapride-like cardiac concern is addressed in the label only as a QT and MACE statement [1], which is not a mitochondrial finding. Framing caution A receptor-level research signal from other agonists. It is not a claim that prucalopride harms, or supports, mitochondria.

Limits on what this shows

• Key null findings: In MPTP-treated mice, prucalopride raised striatal dopamine, improved motor deficits and eased gut barrier impairment [8], but the accessible abstract reports no oxidative-stress marker, so it is not counted as an oxidative-stress measurement. A PubMed listing for prucalopride with oxidative, mitochondria or reactive-oxygen terms returned 18 records [16]; apart from [5] and the commentary on 5-HT4 neuroprotection, none concerned redox biology in prucalopride-treated tissue. One record (PMID 27037978) is tablet-chemistry forced-degradation work, not biology.
• At-risk subgroups: None identified.

Regulatory status

No oxidative-stress statement in the label sections retrieved [1][2].

Population evidence

Bianco et al., Am J Physiol Gastrointest Liver Physiol 2016 [5]: SH-SY5Y cells, human neurospheres and ex vivo human submucosal neurons exposed to H2O2 (200 uM for 30 minutes per the PMC page summary), with or without prucalopride 1 nM. Survival 73.5% with prucalopride vs 33.3% with H2O2 alone (P less than 0.0001), with reduced active caspase-3 and caspase-9; reversed by the 5-HT4 antagonist GR113808. Sample sizes were not captured. Abstract text is a reconstruction from OpenAlex; methods detail came from a summarizing fetch of the PMC page. Drug in cohort: yes (in vitro).

Mechanism

Receptor-mediated anti-apoptotic signaling, not direct antioxidant chemistry (the antagonist abolished the effect [5]). The authors' stated limitations, as summarized from the PMC page, were a 24-hour window, no direct ROS or mitochondrial function measurement and no in vivo validation.

Class cohort test

Not a class extrapolation: prucalopride was the studied drug in [5] and [8].

Counter-evidence held on record

Counter-evidence and confounding The in vitro concentration (1 nM) was not compared with human tissue exposure in this review, and no in vivo or human redox measurement exists. Neuronal survival after an H2O2 insult is an outcome of a cell-death pathway, not a measure of systemic antioxidant capacity. Framing caution A protective in vitro finding. It does not show that prucalopride raises antioxidant capacity and is not a reason to change any supplement. Direction is protective, not depleting.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or C source supports even a yellow grade, and no circulating claim of prucalopride-related copper change was found to rebut. This is a disclosed gap, not a finding of safety. Re-check with a PubMed listing for prucalopride with copper and ceruloplasmin terms when rate limits clear.

What was searched

US label sections 5, 6, 7, 12 and 13 and the EU SmPC sections 4.4, 4.8, 5.1 to 5.3: no copper statement [1][2]. Web search "prucalopride copper OR ferritin OR serum iron OR hematocrit effect": results were generic copper and iron pages, none concerning prucalopride. Web search "prucalopride Motegrity nutrient depletion vitamin deficiency drug-induced": results were label and consumer drug pages plus a general depletion review [14], which does not mention prucalopride. Repair pass: the CHMP assessment report (non-clinical and clinical safety sections) and both EU variation reports were searched for copper and ceruloplasmin: no mention [19][20][21]; the FDA pediatric review has no copper statement [18]; the US label sections 8.4 and 13 were re-read: no copper statement [1]. PubMed listing "prucalopride copper" returned HTTP 429 and the fetch tool asked that it not be retried; an earlier phrasing with copper, ceruloplasmin, zinc and trace element terms also returned 429. OpenAlex and Crossref search endpoints returned 429.

Channel outcomes

Label pages and open web search worked. PubMed listing queries for microbiome and for anemia/hemoglobin/iron returned HTTP 429 and were not read. The organization network policy blocks direct HTTP to PubMed, Crossref, Europe PMC and similar hosts, so those were not routed around. Mixed result: a clean zero across every regulatory document opened and the open web, plus a tooling-limited gap in the literature databases (the web search budget was also exhausted before a final copper phrasing could be tried). Best characterized as a probable genuine gap that could not be fully closed.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or C evidence supports a yellow grade and no circulating claim exists to rebut. Not a finding of safety. Re-check the FDA appendix laboratory tables and a PubMed listing with ferritin and iron terms when access allows.

What was searched

Label and SmPC: no iron, hemoglobin or anemia statement; the EU SmPC lists rectal haemorrhage as uncommon, which is a bleeding adverse event, not an iron-handling finding [1][2]. Web search "prucalopride anemia OR hemoglobin OR iron deficiency 5-HT4 receptor agonist": results were pharmacology and label pages (titles only; none opened addressed iron). FDA advisory briefing [4]: laboratory findings are in appendices not reproduced by the fetch. Drug Safety 2019 cardiovascular cohort (5,715 prucalopride initiators) does not address blood disorders or anemia [13]. NEJM 2008 trial abstract [12] reports efficacy and common adverse effects only. Repair pass: the CHMP assessment report, EU variation II/0034, the EU pediatric assessment and the FDA pediatric review were searched for iron, ferritin, anemia and iron deficiency: none reported a prucalopride iron measurement [18][19][20][21]. The rat finding of lower hematocrit, hemoglobin and red cells with higher MCV and MCH [19] is filed under oxygen delivery/utilization as animal toxicology; iron was not measured there, and anemia is not iron deficiency (Hard Rule 2). Trials of prucalopride in patients with coexisting iron deficiency or iron-induced constipation were looked for in an open web search before the budget ended: results were generic iron-constipation consumer and guideline pages, none a prucalopride trial.

Channel outcomes

In the repair pass, PubMed listings for prucalopride with "anemia" and with "hemoglobin" were opened and returned only unrelated hematology records [25][26]; a Boolean title/abstract query returned 404, and listings with "ferritin" and "copper" returned 429. PMC article pages returned bot-verification. Mixed result: an open-web and regulatory-document zero plus a tooling-limited gap; the pooled adult phase 3 laboratory tables remain unread.

Limits on what this shows

• Key null findings: No change in alpha diversity [6]. A second mouse study of prucalopride (15q duplication model, 1 mg/kg by gavage for 6 days) did not assess microbiota [10]. No human 16S or metagenomic study with prucalopride was located in six web-search phrasings.
• At-risk subgroups: None identified.

Regulatory status

No microbiome statement in the US label or EU SmPC sections retrieved [1][2].

Population evidence

Cussotto et al., npj Biofilms and Microbiomes 2026 [6]: male C57BL/6J mice on chronic corticosterone (CORT), prucalopride 0.5 and 1.5 mg/kg/day by osmotic minipump for 7 and 28 days, compared with fluoxetine; roughly 4 to 10 mice per arm. Chronic prucalopride did not change alpha diversity (Chao1, Shannon) but shifted beta diversity (Bray-Curtis). Ruminococcus, depleted by CORT, was restored at both doses at the chronic timepoint. UBA1819 fell in all CORT groups, so it is not attributable to the drug. Two retrievals summarized the Lactobacillus result differently, so it is not used. Drug in cohort: yes. Read through a summarizing fetch of the journal page [6].

Mechanism

Plausible, not demonstrated. Prucalopride shortens colonic transit [1] and causes diarrhea in 13% of users vs 5% on placebo [1], and transit is a recognized modifier of gut microbiota. In [6] the authors list as limitations genus-level 16S only, no prucalopride-only or fluoxetine-only control groups, and no gut motility measurement, so the shift cannot be separated from the CORT model or from transit.

Class cohort test

Not a class extrapolation: prucalopride was the studied drug in [6]. No data from other 5-HT4 agonists or from sibling dossiers were borrowed.

Counter-evidence held on record

Counter-evidence and confounding Constipation itself is associated with microbiome differences: in slow transit constipation, Shannon and Simpson diversity were higher than in controls [11], and prucalopride was not used in that study. Any human change would therefore be confounded by indication and by transit. The mouse model was stress-induced, not constipation. Framing caution This is a single mouse composition observation, not a claim of dysbiosis, infection risk or harm. It should not be presented to consumers as a risk.

Limits on what this shows

• Key null findings: No clinically relevant human hematology change on mean values [20]. No hemoglobin, anemia or hematologic statement in the US label sections reviewed [1], in the pediatric trial summaries [18][21], or in the Shire FDA advisory presentation as read by the fetch tool [23]. PubMed listings for prucalopride with anemia and with hemoglobin returned only unrelated hematology records [25][26]. No methemoglobin, hemolysis or arterial oxygenation report for prucalopride was found.
• At-risk subgroups: None identified in humans. Severe renal impairment raises prucalopride exposure 2.38-fold [1], which is a dosing matter; the documents reviewed do not relate human exposure at that level to the rat findings.

Regulatory status

The US label sections 8.4 and 13 contain no hematology statement [1]. The CHMP assessment report for Resolor (EMEA/664892/2009), repeat-dose toxicity section, lists the hematological system among target organs in studies of mice (up to 3 months), rats (up to 6 months) and dogs (up to 12 months): "decreased haematocrit, haemoglobin and red blood cells; increased MCV and MCH" in male and female rats at and above 20 mg/kg/day, with a no-effect level of 5 mg/kg/day, "5-12 times the clinical exposure" [19]. The FDA multi-discipline review of the pediatric supplement (NDA 210166/S-004, completed July 9, 2025) reports a 28-day oral juvenile rat study at 5, 20 and 80 mg/kg/day (15 pups per sex per group): slight decreases in hematocrit and hemoglobin were described in both sexes (dose group not captured) and, at 80 mg/kg/day in males, "moderate decreases in hematocrits, hemoglobin, red blood cells, white blood cells and lymphocytes", with a no-effect level of 5 mg/kg/day for males and 20 mg/kg/day for females; reversibility was not addressed for this study [18].

Population evidence

Animal only for the quantified signal. Human data: the EU variation assessment (II/0034, adult men added to the indication) states that mean changes from baseline in biochemistry, hematology and urinalysis were "generally small and none were considered clinically relevant", while noting that "the most common differences in shifts in laboratory parameters between the two groups concerned high prolactin, low erythrocytes and high cholesterol values" in study SPD555-302 (370 subjects, 184 on prucalopride per the fetch summary); no percentage, hemoglobin or hematocrit value is given [20]. The pediatric EU assessment (25 July 2024) and the FDA pediatric review report no hemoglobin, hematocrit or anemia data from the pediatric trial [18][21]. Sample sizes and exact dose-group statistics for the adult rat studies were not captured. All regulatory text was read through a summarizing fetch. Drug in cohort: yes (rats).

Mechanism

Not stated. The CHMP report does not say whether the changes were adverse or attribute them to reduced food intake or a specific anemia mechanism [19]. The accompanying increase in MCV and MCH is not the pattern of iron-deficiency anemia, but no iron, ferritin or erythropoietic marker was reported in the text retrieved, so no iron conclusion is drawn here.

Class cohort test

Not a class extrapolation: prucalopride was the studied drug in the rat studies [18][19]. No data from other 5-HT4 agonists or from sibling dossiers were borrowed.

Counter-evidence held on record

Counter-evidence and confounding Rat findings occur at and above 20 mg/kg/day, with a no-effect level at 5 to 12 times clinical exposure [19]; high-dose toxicology in rodents is a drug toxicity signal, not a nutrient depletion (Hard Rule 2). Human mean hematology changes were judged not clinically relevant [20]. A decrease in hemoglobin or red cells is an outcome, not an iron, copper or oxygen-delivery deficiency; none of those was measured. Framing caution An animal toxicology observation at high exposure. It does not show that prucalopride lowers hemoglobin or oxygen delivery in people and gives no basis to change any iron intake or supplement.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or C evidence of any agonist or prucalopride effect on ATP (a knock-down result is not a drug effect and is recorded in the mitochondrial entry as receptor biology only), and no circulating claim of low energy or ATP loss for prucalopride was found. Not a finding of safety.

What was searched

Web search "5-HT4 receptor agonist prucalopride mitochondrial biogenesis OR oxidative stress OR cardiomyocyte OR ischemia reperfusion in vivo" returned [5], [7] and unrelated cardiac-ischemia papers. In [7] the only ATP datum is a 12.04% fall in intracellular ATP in 5-HTR3 and 5-HTR4 siRNA knock-down cardiomyocytes after 12 hours of anoxia; that is receptor-loss biology, not an agonist or drug effect, and prucalopride was not used. PubMed listing [16] (prucalopride with mitochondria, oxidative, reactive-oxygen terms): no ATP record. Label and SmPC: no ATP statement. Repair pass: PubMed listing prucalopride[Title/Abstract] with ATP, oxygen consumption, respiration or bioenergetic terms opened (6 records) [22]: the only ATP mentions are ATP as an enteric neurotransmitter or macrophage-activating stimulus (PMID 21723862 pig colon; PMID 30472681 mouse ileus, abstract text seen only as a listing excerpt), not cellular energy output; the other four were horse, laxative-extract and congress-abstract records with no ATP content. A mosapride (not prucalopride) postoperative-ileus paper opened from a web search measured no ATP or mitochondrial parameters [24]. Web searches for prucalopride with cardioprotection, ischemia-reperfusion, mitochondria and ATP returned only unrelated cardiac-ischemia papers. Regulatory documents [18][19][20][21] contain no ATP or mitochondrial statement. Label fatigue (2% vs 1%) and decreased appetite (under 2%) are adverse reactions, not an ATP finding [1].

Channel outcomes

Two PubMed listings opened (18 records [16], 6 records [22]); PMC article pages returned bot-verification; the web search budget ended before a sepsis or ischemia-specific second phrasing could be run. Best characterized as a genuine gap in the literature reached, with the primary databases searched with two independent phrasings.